» Authors » Tamar E Bacon

Tamar E Bacon

Explore the profile of Tamar E Bacon including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 294
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Quinn C, Rajarajan P, Gill A, Kopinsky H, Wolf A, de Camargo C, et al.
Neurology . 2024 Nov; 103(11):e210003. PMID: 39541548
Background And Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with...
2.
Kister I, Curtin R, Piquet A, Borko T, Pei J, Banbury B, et al.
Ann Clin Transl Neurol . 2024 May; 11(7):1750-1764. PMID: 38713096
Objectives: (1) To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up...
3.
Kister I, Oh C, Douglas E, Bacon T, OShea I, Parrotta E, et al.
Neurol Clin Pract . 2023 Sep; 13(5):e200185. PMID: 37674871
Background And Objectives: Some patients with multiple sclerosis (MS) receiving ocrelizumab (OCR) report worsening symptoms toward the end of the 6-month infusion cycle ('wearing off'). The objective of our study...
4.
Kister I, Curtin R, Pei J, Perdomo K, Bacon T, Voloshyna I, et al.
Ann Clin Transl Neurol . 2022 Sep; 9(10):1643-1659. PMID: 36165097
Objective: To compare "hybrid immunity" (prior COVID-19 infection plus vaccination) and post-vaccination immunity to SARS CoV-2 in MS patients on different disease-modifying therapies (DMTs) and to assess the impact of...
5.
Kalincik T, Kister I, Bacon T, Malpas C, Sharmin S, Horakova D, et al.
Mult Scler . 2022 Apr; 28(11):1752-1761. PMID: 35373638
Background: The MSBase prediction model of treatment response leverages multiple demographic and clinical characteristics to estimate hazards of relapses, confirmed disability accumulation (CDA), and confirmed disability improvement (CDI). The model...
6.
Kister I, Patskovsky Y, Curtin R, Pei J, Perdomo K, Rimler Z, et al.
Ann Neurol . 2022 Mar; 91(6):782-795. PMID: 35289960
Objective: The objective of this study was to determine the impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to severe acute respiratory...
7.
Eilam-Stock T, Links J, Khan N, Bacon T, Zuniga G, Laing L, et al.
Health Psychol Open . 2021 Oct; 8(2):20551029211052830. PMID: 34707881
Objective: At the time of multiple sclerosis (MS) diagnosis, identifying those at risk for poorer health-related quality of life and emotional well-being can be a critical consideration for treatment planning....
8.
Kister I, Bacon T, Cutter G
Ther Adv Neurol Disord . 2018 Sep; 11:1756286418793613. PMID: 30214486
Background: Short-term disease progression is well documented in clinical trials, but there are limited published data on disease course in real-life practice. Methods: Patient-derived Multiple Sclerosis Severity Score (PMSSS), a...
9.
Longbrake E, Kantor D, Pawate S, Bradshaw M, Geldern G, Chahin S, et al.
Neurol Clin Pract . 2018 May; 8(2):102-107. PMID: 29708225
Background: Fingolimod is a daily oral medication used to treat relapsing multiple sclerosis (MS). Clinicians often adopt less frequent dosing for patients with profound drug-induced lymphopenia or other adverse events....
10.
Fox R, Bacon T, Chamot E, Salter A, Cutter G, Kalina J, et al.
Neurodegener Dis Manag . 2015 Nov; 5(6 Suppl):3-10. PMID: 26611264
The North American Research Committee on Multiple Sclerosis is a voluntary patient registry with more than 38,000 registrants as of 2015. In a recent collaborative project, longitudinal data on patient-perceived...